Breast Tissue Marker Systems

Aug 21, 2003
Breast Tissue Marker Systems
VENDOR PRODUCT NAME &
DEVICE CATEGORY 		SPECIFICATIONS
InRad
Kentwood, MI 		UltraClip 2 -- accessory
  • 3-mm titanium tissue marker for breast biopsy follow-up.
  • Visible with mammography and ultrasound.
    		•
    Ethicon Endo-Surgery
    Cincinnati, OH     		MicroMark II -- accessory
  • Tissue marker for postoperative breast biopsy monitoring.
  • Undetectable to patient, allows physician to keep track of an abnormality in future mammograms.
    • Artemis Medical
    Hayward, CA     		Mammomark --accessory
  • Collagen-based self-expanding breast biopsy marker with titanium clip.
  • After placement, hydrates, conforms to size and shape of biopsy cavity, can be visualized mammographically and on ultrasound.
  • Resorbs within weeks, leaving clip for long-term follow-up.
    		•
    SenoRx
    Aliso Viejo, CA     		Gel Mark -- accessory
  • Gelatin-based biopsy site marker visualized using ultrasound, mammography, and digital mammography.
  • Compatible with Mammotome and MIBB.
  • Disposable device releases gelatin pellets that hydrate and swell within the biopsy cavity, resorbing within a few weeks.
    		•
    Latest in Womens Imaging
    Coffta Sandy Thumbnail
    Current topics in mammography
    January 17, 2025
    Contrast Injector
    CEM has slightly higher mean glandular dose than DBT, mammography
    January 16, 2025
    Ultrasound Portable
    POCUS useful for diagnosis of retained conception tissue
    January 15, 2025
    Mammo Reading Social
    CEM-, radiomics-based models predict breast biopsy outcomes
    January 13, 2025
    Related Stories
    Cc99 Ff Dot
    Breast
    Effective breast CAD still harbors a few workflow caveats
    2003 04 25 14 48 38 706
    Breast
    Breast cancer in younger women calls for flexibility in imaging
    2003 04 10 15 09 19 706
    Breast
    Contrast-enhanced 3-D US boosts mammography results
    2003 01 13 15 29 39 706
    Breast
    Start-up firm Photonify sees promise in optical imaging
    More in Womens Imaging
    Current topics in mammography
    By Sandy Coffta
    Sandy Coffta of Healthcare Administrative Partners discusses changes in reporting and reimbursement for mammography exams.
    January 17, 2025
    Coffta Sandy Thumbnail
    CEM has slightly higher mean glandular dose than DBT, mammography
    By Amerigo Allegretto
    Contrast-enhanced mammography (CEM) has a slightly higher mean glandular dose than other breast imaging modalities.
    January 16, 2025
    Contrast Injector
    POCUS useful for diagnosis of retained conception tissue
    By Amerigo Allegretto
    Point-of-care ultrasound (POCUS) can be a useful tool for diagnosing the presence of retained conception tissue.
    January 15, 2025
    Ultrasound Portable
    CEM-, radiomics-based models predict breast biopsy outcomes
    By Amerigo Allegretto
    Machine-learning models combining features from radiomics and contrast-enhanced mammography (CEM) can predict breast biopsy outcomes in women.
    January 13, 2025
    Mammo Reading Social
    Genetic testing, risk assessment tied to more breast MRI uptake
    By Amerigo Allegretto
    Women with high-risk pathological variants for breast cancer as identified by genetic testing and risk assessment are more likely to undergo breast MRI.
    January 13, 2025
    Mri Breast 400
    DBT on par with mammography for imaging referred women
    By Amerigo Allegretto
    Digital breast tomosynthesis (DBT) has a diagnostic accuracy comparable to digital mammography for women referred for breast imaging.
    January 10, 2025
    Breast Dbt Social
    AI-supported mammography is safe and effective in real-world settings
    By Amerigo Allegretto
    A prospective study found that AI-supported mammography screening is effective in a nationwide, real-world setting.
    January 8, 2025
    Breast Mammo Computer 400 (1)
    Women with BRCA1/2 germline mutations are often denied breast MRI
    By Kate Madden Yee
    Women with BRCA1/2 germline mutations are often denied breast MRI -- despite the fact that the exam is recommended for this population.
    January 3, 2025
    Mri Breast Cancer
    Starting breast cancer screening at 40 is more cost-effective
    By Amerigo Allegretto
    Starting breast cancer screening at age 40 is tied to improved patient outcomes and reduced healthcare spending on treatment.
    January 3, 2025
    Women Cancer Patient
    Deep learning plus DCE-MRI predicts breast cancer treatment response
    By Amerigo Allegretto
    A deep-learning system based on DCE-MRI can predict pathological complete response in breast cancer patients.
    January 2, 2025
    Mri Breast Cancer
    2009 USPSTF guidelines not linked to higher breast cancer incidence
    By Amerigo Allegretto
    Breast cancer screening guidelines issued in 2009 have not led to increased or decreased breast cancer incidence.
    December 27, 2024
    Breast Cancer3 400 (2)
    40% of women in their 40s forgo biennial breast cancer screening
    By Amerigo Allegretto
    About two in every five women in their 40s do not undergo biennial breast cancer screening per USPSTF recommendations.
    December 20, 2024
    Mammogram Patient
    Page 1 of 681
    Next Page